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Abstract. 
 
Huntington disease is an autosomal domi-
nant neurodegenerative disorder caused by the patho-
logical expansion of a polyglutamine tract. In this study 
we directly assess the influence of protein size on the 
formation and subcellular localization of huntingtin ag-
gregates. We have created numerous deletion con-
structs expressing successively smaller fragments of 
huntingtin and show that these smaller proteins con-
taining 128 glutamines form both intranuclear and peri-
nuclear aggregates. In contrast, larger NH
 
2
 
-terminal 
fragments of huntingtin proteins with 128 glutamines 
form exclusively perinuclear aggregates. These aggre-
gates can form in the absence of endogenous hunting-
tin. Furthermore, expression of mutant huntingtin re-
sults in increased susceptibility to apoptotic stress that 
is greater with decreasing protein length and increasing 
polyglutamine size. As both intranuclear and perinu-
clear aggregates are clearly associated with increased 
cellular toxicity, this supports an important role for 
toxic polyglutamine-containing fragments forming ag-
gregates and playing a key role in the pathogenesis of 
Huntington disease.
 
H
 
untington
 
 disease (HD)
 
1
 
 is one of eight neurode-
generative disorders associated with CAG expan-
sion (Ross, 1995; Andrew et al., 1997). Recently,
new insights have been gained as to how CAG expansion
might be associated with cell death. Intranuclear inclu-
sions have been demonstrated both in vitro and in vivo
 
 
 
in
spinocerebellar ataxia type I (Skinner et al., 1997), type III
(Paulson et al., 1997), Huntington disease (Becher et al.,
1997; Davies et al., 1997; DiFiglia et al., 1997; Martindale
et al., 1998), and dentatorubropallidoluysian atrophy
(DRPLA) (Igarashi et al., 1998). These inclusions contain
the respective gene products and only occur in the pres-
ence of an expanded polyglutamine tract.
We have previously shown that expression of a trun-
cated form of huntingtin (up to amino acid 548) forms
perinuclear aggregates (Martindale et al., 1998). In con-
trast, a small huntingtin fragment corresponding to exon 1
encoding a protein product of 
 
,
 
20 kD and composed al-
most entirely of the polyglutamine tract clearly enters the
nucleus and forms aggregates in vitro (Martindale et al.,
1998) and in vivo (Davies et al., 1997). To directly assess
the relationship between protein size and nuclear import
of huntingtin, we have created progressive truncations of
huntingtin and assessed how the length of the protein in-
fluences its subcellular localization and aggregate forma-
tion.
In mammalian cells, the nucleus is enclosed by an enve-
lope that is intimately associated with the endoplasmic
reticulum. The nuclear envelope is punctured at intervals
by nuclear pores that are the sites of exchange of mole-
cules between the nucleus and the cytoplasm. Small pro-
teins can diffuse freely through the nuclear pore whereas
proteins 
 
.
 
40 kD generally have delayed transport (Gor-
lich and Mattaj, 1996). For proteins 
 
.
 
60 kD, passive diffu-
sion is prevented and nuclear import is dependent on ac-
tive transport (Goldfarb et al., 1986; Newmeyer et al.,
1986; Zasloff, 1983; Dingwall and Laskey, 1991).
In an effort to directly explore the relationship between
the size of the protein and its subcellular localization, we
have created a series of cDNA deletion constructs that ex-
press huntingtin proteins of different molecular weights.
Additionally, we also have shown that even though wild-
type huntingtin is recruited into aggregates (Martindale et
al., 1998), aggregates are able to form in the absence of the
endogenous huntingtin. Second, the findings of this study
reveal that huntingtin molecules of 47 kD and greater are
not transported across the nuclear pore. By contrast,
smaller NH
 
2
 
-terminal fragments of huntingtin can traverse
the nuclear pore complex, which suggests that very small
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disease; HEK, human embryonic kidney.
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huntingtin fragments are transported into the nucleus
mainly via passive diffusion.
The exact relationship between pathology and hunting-
tin aggregates in vivo is not clear. In an in vitro cell culture
model we have demonstrated that the formation of peri-
nuclear aggregates are associated with increased suscepti-
bility to cell death (Martindale et al., 1998). In the present
study, we determine the influence of the length of the hun-
tingtin protein on cell death. Here, we show that progres-
sive truncations of huntingtin are correlated with an in-
creasingly severe susceptibility to an apoptotic stress. The
findings of intranuclear inclusions (DiFiglia et al., 1997)
associated with cytoplasmic perinuclear accumulation of
huntingtin (Sapp et al., 1997) in the neurons of patients
with Huntington disease, together with findings of this pa-
per, provide significant support for the toxic fragment
model for the pathogenesis of HD (Goldberg et al., 1996;
Wellington and Hayden, 1997), whereby proteolytic cleav-
age of huntingtin liberates an NH
 
2
 
-terminal fragment con-
taining the glutamine tract that forms aggregates, which
confer increased susceptibility to death from apoptotic
stimuli.
 
Materials and Methods
 
Vector Construction
 
Expression constructs containing the full-length huntingtin cDNA
(pRcCMV10366-15 and pRcCMV10366-128) or the first 1955 nucleotides
of the huntingtin cDNA (pCI1955-15 and pCI1955-128) have been de-
scribed previously (Goldberg et al., 1996; Martindale et al., 1998). Site-
directed mutagenesis was used to create a series of additional NH
 
2
 
-termi-
nal truncations of huntingtin by introducing a translational termination
codon at defined positions in the 1955-15 and 1955-128 constructs using
the Transformer Mutagenesis kit (CLONTECH, Palo Alto, CA). Termi-
nation codons were inserted at nucleotide position 436, 771, 989, and 1597
as defined for huntingtin in GenBank/EMBL/DDBJ under accession num-
ber L27350. The following mutagenesis primers were used: 436-15 and 436-
128: 5
 
9
 
-CAGCAGCAGCAGCAACAGTGACCACCGCCGCCGCCG-3
 
9
 
;
771-15 and 771-128: 5
 
9
 
-GGCTGACGAATGACTCAACAAAG-3
 
9
 
; 989-15
and  989-128: 5
 
9
 
-GACCCGAAGAATGAGTCCAGGAG-3
 
9
 
; 1597-15 and
1597-128: 5
 
9
 
-GAACTTATAGCTTGAGGGGGTTCC-3
 
9
 
.
The selection primer for each mutagenesis was 5
 
9
 
-CATGGCTCGA-
CACATGTTCAATATTG-3
 
9
 
. Authenticity of the mutagenized con-
structs was confirmed by DNA sequencing. Also, a huntingtin COOH-ter-
minal construct, encoding amino acids 585–3,144, was constructed by
standard subcloning as described (Wellington et al., 1998).
 
Immunofluorescence and Western Blotting
 
Human embryonic kidney cells (HEK 293T) were grown on glass cover-
slips in DME (Gibco Laboratories, Grand Island, NY) with 10% FBS and
antibiotics, in 5% CO
 
2
 
 at 37
 
8
 
C. The cells were transfected at 30% conflu-
ency with the calcium phosphate protocol by mixing Qiagen-prepared
DNA (QIAGEN Inc., Chatsworth, CA) with 2.5 M CaCl
 
2
 
, and then incu-
bating at room temperature for 10 min. 2
 
3
 
 Hepes buffer (240 mM NaCl,
3.0 mM Na
 
2
 
HPO
 
4
 
, 100 mM Hepes, pH 7.05) was added to the DNA/cal-
cium mixture, incubated at 37
 
8
 
C for 60 s, and then added to the cells. Af-
ter 12–18 h, the media was removed, the cells were washed, and fresh me-
dia was added. At 36 h after transfection, the cells were treated with 35 
 
m
 
M
tamoxifen (Sigma Chemical Co., St. Louis, MO) for 1 h, and then pro-
cessed for immunofluorescence. The cells were washed with PBS, fixed in
4% paraformaldehyde/PBS solution for 20 min at room temperature, and
then permeabilized in 0.5% Triton X-100/PBS for 5 min. After three PBS
washes, the cells were incubated with anti-huntingtin antibody mAb 2166
(Chemicon International Inc., Temecula, CA) (1:2,500 dilution) or BKP1
(1:100 dilution) (Kalchman et al., 1997) in 0.4% BSA/PBS for 1 h at room
temperature in a humidified container. The primary antibody was re-
moved, the cells were washed, and secondary antibodies conjugated to
Texas red or FITC were added at a 1:600–1:800 dilution for 30 min at
room temperature. The cells were then washed again, and the coverslips
were mounted onto slides with DAPI (4
 
9
 
,6
 
9
 
-diamidino-2-phenylindole;
Sigma Chemical Co.) as a nuclear counterstain. Immunofluorescence was
viewed using an Axioscope microscope (Carl Zeiss, Inc., Thornwood,
NY), digitally captured with a CCD camera (Princeton Instrument Inc.,
Trenton, NJ) and the images were colorized and overlapped using the
Eclipse software program (Empix Imaging Inc., Mississauga, ON). Intra-
nuclear localization was determined by colocalization of huntingtin stain
with the DAPI nucleus. The proportion of nuclear and cytoplasmic local-
ization is presented as a percent of the total huntingtin-expressing cells.
Appropriate control experiments were performed to determine the speci-
ficity of the antibody, including secondary antibody only and mock-trans-
fected cells.
To determine the expression levels of truncated huntingtin, transfected
293T cells were harvested by gentle scraping 36 h after transfection. The
cells were pelleted, washed with PBS, and then lysed. Equal amounts of
protein were loaded onto standard 7.5% SDS-PAGE gels or 5–20% gradi-
ent SDS-PAGE gels, transferred onto polyvinylidene difluoride (PVDF)
membrane, Western blotted using anti-huntingtin antibody BKP1 (Kalch-
man et al., 1997), and then detected using enhanced chemiluminescence
(Amersham Corp., Arlington Heights, IL).
 
Size-exclusion Chromatography
 
Size exclusion was performed using a 16/60-cm Sephacryl S-300 high reso-
lution column calibrated with a HMW Gel Filtration Calibration Kit
(Pharmacia Biotechnology Inc., Piscataway, NJ) using run buffer (5 mM
MgCl
 
2
 
, 0.5 mM EDTA, 1 mM PMSF in 1
 
3
 
 PBS buffer, pH 7.3) at a flow
rate of 0.25 ml/min. The void volume was calculated to be 42 ml using
Blue Dextran. A 10-cm plate of 293T cells was transfected with HD 1955-
128 and harvested after tamoxifen treatment. The cells were washed with
ice-cold PBS, suspended in 200 
 
m
 
l of 1
 
3
 
 PBS, and then lysed using 1 ml of 18
mM CHAPS, 5 mM MgCl
 
2
 
, 0.5 mM EDTA in 1
 
3
 
 PBS buffer, pH 7.3, con-
taining complete protease inhibitor cocktail (Boehringer Mannheim
Corp., Indianapolis, IN) for 30 min on ice. Fractions were collected in run
buffer at 0.25 ml/min at 4
 
8
 
C.
 
Cell Viability Assays
 
The viability of 293T cells expressing the huntingtin constructs was as-
sessed by a modified MTT assay (Carmichael et al., 1987; Vistica et al.,
1991). The cells were seeded at a density of 5 
 
3 
 
10
 
4
 
 cells into 96-well
plates and transfected with the huntingtin constructs or the control con-
struct 
 
lacZ
 
 using the calcium phosphate method described above. At 48 h
after transfection, a sublethal concentration of tamoxifen (35 
 
m
 
M) (Could-
well et al., 1994) was added to the cells for 3 h. For the modified MTT as-
say, tamoxifen-treated or untreated cells were incubated for 2 h in a 1:10
dilution of WST-1 reagent (Boehringer Mannheim Corp.) and release of
formazan from mitochondria was quantified at 450 nm using an ELISA
plate reader (Dynatech Laboratories, Chantilly, VA) (Mosmann, 1983;
Carmichael et al., 1987). One-way analysis of variance and Newman-Keuls
tests were used for statistical analysis. The transfection efficiency, mea-
sured by 
 
b
 
-galactosidase staining and immunofluorescence, was 
 
z
 
50%.
 
Transfection of Mouse Embryonic Stem Cells
 
Wild-type and HD
 
2
 
/
 
2
 
 embryonic stem (ES) cells were plated onto 25-mm
cover glass coated with 0.1% gelatin in H
 
2
 
O in six-well plates (Falcon
Plastics, Cockeysville, MD) at a density of 10
 
5
 
 cells per well. Cells were
cultured in media as described previously (Metzler et al., 1994) and trans-
fected with 5 
 
m
 
g of DNA by lipofection using the cationic compound
 
N
 
-[1-(2,3-Dioleoyloxy)propyl]-
 
N
 
,
 
N
 
,
 
N
 
-trimethylammoniummethylsulfate
(DOTAP; Boehringer Mannheim Corp.). The media was changed the fol-
lowing day, and 36 h after transfection cells were incubated in 35 
 
m
 
M
tamoxifen for 90 min. Subsequently, cells were washed twice with PBS
fixed with 4% paraformaldehyde and immunostained with mAb 2166 as
described above.
 
Results
 
Small Fragments of Huntingtin Enter the Nucleus
 
We have demonstrated that huntingtin truncated within
exon 1, composed of 40 amino acids and the polyglutamine 
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tract, can enter the nucleus (Martindale et al., 1998). Fur-
thermore, intranuclear aggregates are formed in neurons
from transgenic mice expressing truncated huntingtin con-
taining exon 1 with an expanded polyglutamine tract
(Davies et al., 1997). In contrast, full-length huntingtin or
huntingtin proteins truncated at amino acid 548 (nucle-
otide 1955) (Fig. 1 
 
a
 
) are not found within the nucleus and
accumulate in the cytosol, particularly in the perinuclear
region. To demarcate functional domains within hunting-
tin that may determine its cellular localization, we created
a set of constructs expressing various regions of huntingtin
and determined the subcellular localization of their
expressed products via indirect immunofluorescence of
transfected cells.
Subcellular localization of this series of truncated con-
structs (Fig. 1 
 
a
 
) was evaluated in an in vitro model system
that we have described previously (Martindale et al.,
1998). In this system, an apoptotic stress is induced in tran-
siently transfected HEK 293T cells with sublethal levels
(35 
 
m
 
M) of the apoptotic agent tamoxifen at 36–40 h after
transfection. After 60 min of tamoxifen treatment, the
cells are processed for indirect immunofluorescence. In
293T cells transfected with 1955 or full-length (10366)
huntingtin cDNA constructs containing 128 glutamines,
not treated with tamoxifen, huntingtin was diffusely ex-
pressed throughout the cytoplasm, with perinuclear aggre-
gates present in only a low frequency of cells (
 
z
 
1%).
However, treatment of these cells with tamoxifen signifi-
cantly increased the proportion of cells with perinuclear
aggregates (Table I 
 
a
 
).
To assess how protein length alters the subcellular local-
ization of huntingtin, HEK 293T cells were transiently
transfected with the 436, 771, 989, 1597, 1955, full-length
(10366), and COOH-terminal contructs (Table I 
 
a
 
; Fig. 1
 
a
 
), each containing 15 and 128 CAG repeats under the
control of the human cytomegalovirus promoter. Protein
products of 
 
z
 
3, 16, 24, 47, 59, and 347 kD are expected
from these respective constructs containing 15 repeats
(Fig. 1 
 
b
 
), whereas proteins with expanded polyglutamine
tracts would migrate as larger protein products (Table I 
 
b
 
).
Indirect immunofluorescence studies were performed be-
fore and after the addition of tamoxifen using anti-hun-
tingtin antibodies mAb2166 or BKP1 that recognize the
NH
 
2
 
 terminus of huntingtin. Both antibodies gave the
same results. Nuclear localization was determined by colo-
calization with DAPI (Fig. 2 
 
a
 
) or the nuclear protein p53
(data not shown).
After transfection of the 436, 771, and 989 constructs,
aggregates were present for each construct with and with-
out tamoxifen treatment at similar frequencies, in contrast
to the transfection of 1955 and 10366 constructs that re-
sulted in aggregates only after treatment with tamoxifen.
These aggregates appear as large, irregularly shaped depo-
sitions of huntingtin (Fig. 2 
 
a
 
). Size-exclusion chromatog-
raphy demonstrated that the huntingtin forms stable high
molecular weight complexes that do not denature in SDS-
PAGE (Fig. 2 
 
b
 
).
The subcellular localization of different huntingtin frag-
ments varied according to the size of the protein product
(Fig. 2 
 
a
 
; Table I 
 
b
 
) and was similar with and without apop-
totic stress. Protein products derived from the three small-
est constructs (436, 771, and 989) expressing the most 40,
151, and 224 NH
 
2
 
-terminal residues of huntingtin were
each able to enter the nucleus with both 15 and 128
glutamines. However, the frequency of nuclear entry var-
ied among the constructs tested. For example, the localiza-
tion of aggregates formed by expression of the 436-128
and 989-128 constructs was divided between the nuclear
Figure 1. (a) Diagrammatic representation of the cDNA expression constructs used in this study. Bars represent huntingtin protein,
with amino acids numbered according to GenBank/EMBL/DDBJ accession number L27350. The locations of the polyglutamine tract
(Q) are indicated. The names of the constructs, 436, 771, 989, 1597, 1955, and 10366 correspond to the nucleotide position of the transla-
tion termination codon. The amino acid length of each protein is also indicated at the right. (b) Western blot of huntingtin truncation
constructs. HEK 293T cells were transfected with the 771, 989, 1597, 1955, and 10366 constructs, containing 15 glutamines. 36 h after
transfection, cell lysates were prepared. Equal amounts of protein were loaded on a 5–20% SDS-PAGE gradient gel, and Western blot-
ted using anti-huntingtin antibody BKP1, which recognizes the NH2 terminus. Multiple bands in the lanes represent different conforma-
tions of the protein or huntingtin multimers. The amino acid length (aa) of each expressed protein is also indicated. 
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and perinuclear regions (Fig. 2 
 
a
 
), whereas expression of
the larger product (31 kD) from the 771-128 construct re-
sulted in more cells with nuclear than perinuclear aggre-
gates (Fig. 2 
 
a
 
; Table I 
 
b
 
). In contrast, expression of
the 1597, 1955, and 10366 constructs with 15 and 128
glutamines resulted in exclusive cytoplasmic localization
of the gene products. Aggregates formed after transfection
with 1597-128, 1955-128, and 10366-128 constructs were
only observed in the perinuclear region (Fig. 2 
 
a
 
; Table I
 
b
 
). In addition, cells transfected with a construct contain-
ing the COOH-terminal region of huntingtin (amino acids
585–3,144) did not form aggregates, and the COOH-termi-
nal portion of huntingtin was located diffusely throughout
the cytoplasm before and after (Fig. 3) tamoxifen treatment.
The frequency of aggregates varied between constructs
of different lengths containing the same number of poly-
glutamines. An increased frequency of aggregates was
seen in cells expressing shorter huntingtin products than in
cells transfected with the 1955-128 and 10366-128 con-
structs (Table I 
 
a
 
). HEK 293T cells were also transiently
transfected with the same series of constructs expressing
15 glutamines (Table I 
 
c
 
) that did not form aggregates al-
though the subcellular localization of the gene product
was similar to that seen after expression of the constructs
with 128 repeats (Fig. 4; Table I 
 
b
 
).
 
Aggregates Can Form in the Absence of Full-Length 
Endogenous Huntingtin
 
To further understand which factors contribute to the for-
mation of aggregates, we determined whether endogenous
huntingtin was required. Using immunofluorescent confo-
cal microcopy and antibodies directed to epitopes within
the NH
 
2
 
- and COOH-terminal portions of huntingtin
(Hodgson et al., 1996; Martindale et al., 1998), we have
previously shown that aggregates containing truncated
 
Table I.
 
(
 
a
 
) Frequency of Aggregate Formation in Transfected Cells (%)
Construct 436-(128) 771-(128) 989-(128) 1597-(128) 1955-(128) 10336-(128)
 
Without tamoxifen 45 81 70 4 0-1 0-1
 
n
 
 
 
5
 
 3
 
n
 
 
 
5
 
 1
 
n
 
 
 
5
 
 1
 
n
 
 
 
5
 
 2
 
n
 
 
 
5
 
 5
 
n
 
 
 
5
 
 5
With tamoxifen 43 92 78 13 27 9
 
n
 
 
 
5
 
 4
 
n
 
 
 
5
 
 3
 
n
 
 
 
5
 
 2
 
n
 
 
 
5
 
 2
 
n
 
 
 
5
 
 4
 
n
 
 
 
5
 
 4
 
(
 
b
 
) Subcellular Localization of Huntingtin Aggregates with 128 Polyglutamines in 293T Cells (%)
Construct 436-(128) 771-(128) 989-(128) 1597-(128) 1955-(128) 10336-(128)
 
Predicted protein size (kD) 18 31 39 61 73 362
Estimated* size (kD) ND 68 75 77 115 530
Without tamoxifen
Nuclear 21 77 22 0 0 0
Cytoplasmic 79 23 78 100 0-1 0-1
No. of cells counted 288 176 66 427
 
.
 
1,000 .1,000
n 5 3 n 5 3 n 5 2 n 5 2 n 5 5 n 5 5
With tamoxifen
Nuclear 36 71 38 0 0 0
Cytoplasmic 64 29 62 100 100 100
No. of cells counted 314 175 95 320 .1,500 .1,000
n 5 4 n 5 3 n 5 2 n 5 2 n 5 5 n 5 5
(c) Subcellular Localization of Huntingtin Protein with 15 Polyglutamines in 293T Cells
Length/size
nucleotides 436-(15) 771-(15) 989-(15) 1597-(15) 1955-(15) 10366-(15) COOH terminus
Amino acids 1–40 1–151 1–224 1–427 1–548 1–3,144 585–3,144
Predicted protein size (kD) 3 16 24 47 59 347 284
Estimated size* ND 40 43 72 80 370 280
Localization without tamoxifen (%)
Nuclear 21 86 11 0 0 0 0
Cytoplasmic 79 14 89 100 100 100 100
No. of cells counted 250 185 202 321 .1,000 .1,000 .200
n 5 2 n 5 3 n 5 2 n 5 2 n 5 5 n 5 6 n 5 1
Localization with tamoxifen (%)
Nuclear 57 82 21 0 0 0 0
Cytoplasmic 43 18 79 100 100 100 100
No. of cells counted 181 337 85 319 .400 .1,000 .200
n 5 2 n 5 2 n 5 2 n 5 2 n 5 5 n 5 5 n 5 2
Numbers in brackets indicate the polyglutamine length. ND, not detected.
*Estimated by electrophoretic migration on Western blot. The polyglutamine tract causes aberrant migration.Hackam et al. Aggregates and Toxicity of Huntingtin Proteins 1101
huntingtin comprise not only the NH2-terminal fragment,
but also contain the COOH terminus of the endogenous
protein that was not encoded by the transfected cDNA
(Martindale et al., 1998). The fact that COOH-terminal
staining was present in aggregates in cells transfected with
constructs expressing only truncated NH2-terminal hun-
tingtin suggested that endogenous huntingtin was re-
cruited into these aggregates. The question then arises
whether full-length endogenous huntingtin is necessary for
the formation of aggregates associated with expression of
truncated mutant huntingtin.
HD2/2 ES cells are homozygous for a targeted mutation
within exon 5 of the HD gene (Nasir et al., 1995) and
therefore lack full-length huntingtin expression. In ES
cells, we are unable to detect a truncated huntingtin prod-
uct and therefore if initially present, it is likely to be rap-
idly degraded in this cell system. Wild-type and HD2/2 ES
cells were transfected with a truncated form of huntingtin
(construct 1955) with 15 or 128 CAG repeats. After
tamoxifen treatment, wild-type and HD2/2 ES cells trans-
fected with constructs expressing huntingtin with 15
glutamines (1955) had no (wild-type) or very few (1% for
HD2/2 ES) aggregates. In contrast, the frequency of ag-
gregates was increased in both wild-type (3%) and HD2/2
ES cells (6.8%) transfected with huntingtin expressing 128
glutamines (1955-128) (Fig. 5). The aggregates were in the
perinuclear region of the ES cells. These results clearly
show that the presence of full-length endogenous hunting-
Figure 2. (a) Immunofluo-
rescence of 293T cells trans-
fected with the 436, 771, 989,
1597, 1955, and 10366 con-
structs, each containing 128
glutamines. 36–40 h after
transfection, the cells were
processed for immunofluo-
rescence using mAb 2166
(red) or BKP1 (green) to de-
tect huntingtin. The cells
were counterstained with
the DNA stain DAPI (blue)
to label the nucleus (the
DAPI stain is not visible in
the cells shown for 1597-128
and 10366-128). Huntingtin
located in the nucleus ap-
pears pink as the red stain is
overlaid with blue. Hunting-
tin from the 436, 771, and 989
constructs (top row) appears
as large intranuclear aggre-
gates. Huntingtin from the
1597, 1955, and 10366 constructs (bottom row) show perinuclear aggregates and diffuse cytoplasmic stain. (b) Size-exclusion chromatog-
raphy of a lysate from 293T cells transfected with HD1955-128 and treated with tamoxifen. 1-ml fractions were collected at 48C, and
samples were immediately analyzed by reducing SDS-PAGE and Western blotting with BKP1 antibody. Large molecular weight com-
plexes were not retained by the column and flowed through into the void volume. Huntingtin aggregates isolated in the void volume
were observed as species that did not denature upon SDS-PAGE and did not exit the stacking gel (Vo 5 42 ml; lanes 2 and 3). Under the same
conditions, no aggregation was observed in the whole cell lysate (lane 1) nor in the monomeric huntingtin fractions (V 5 72 ml; lanes 4
and 5). Bar in a: (436-128) 11.3 mm; (771-128) 5.31 mm; (989-128) 11.2 mm; (1597-128) 11.97 mm; (1955-128) 12 mm; (10366-128) 11.4 mm. 
Figure 3. Immunofluorescence
of 293T cell transfected with
the COOH-terminal hunting-
tin construct (amino acids
585–3,144). Transfected cells
were treated with tamoxifen
36–40 h after transfection
and processed for immuno-
fluorescence using mAb 2172
to detect huntingtin (red).
The protein was localized ex-
clusively throughout the cy-
toplasm. Bar, 4.42 mm.The Journal of Cell Biology, Volume 141, 1998 1102
tin is not necessary or critical for formation of aggregates
after transfection of truncated huntingtin with the ex-
panded polyglutamine tract.
Increased Susceptibility to Cell Death Is
Correlated with Aggregate Formation and Inversely 
Correlated with Length of Huntingtin
We have previously demonstrated that expression of mu-
tant huntingtin results in increased susceptibility to an apop-
totic stress in transfected 293T cells induced by sublethal
doses of tamoxifen (Martindale et al., 1998). Furthermore,
the 1955 constructs resulted in significantly more cell
death than the full-length huntingtin constructs (Martin-
dale et al., 1998). To determine whether this observed dif-
ference represented a graded effect resulting from protein
length, we assessed the change in viability of cells after ex-
pression of huntingtin of different lengths.
293T cells were transiently transfected with the series of
huntingtin truncation and full-length constructs and the vi-
ability of the transfected cells was assessed by a modified
MTT assay that measures mitochondrial function (Mos-
mann, 1983; Carmichael et al., 1987; Vistica et al., 1991).
Mock- and LacZ-transfected 293T cells treated with
tamoxifen served as controls. In each assay, cells trans-
fected with the truncated constructs exhibited significantly
higher proportions of injury or death compared with cells
that received full-length huntingtin containing the same
polyglutamine length (P , 0.01) (Fig. 6). Interestingly, this
was seen even with proteins with 15 glutamines indicating
Figure 4. Immunofluorescence
of 293T cells transfected with
the 436, 771, 989, 1597, 1955,
and 10366 constructs, each
containing 15 glutamines.
The transfected cells were
treated with tamoxifen 36-40 h
after transfection and mAb
2166 (red) or BKP1 (green)
was used to detect hunting-
tin. The cells were counter-
stained with the DNA stain
DAPI (blue) (the DAPI stain
is not visible in the 1597-15
panel). Huntingtin contain-
ing 15 repeats does not form
aggregates but can be local-
ized in the nucleus depend-
ing on the protein size. Hun-
tingtin is localized entirely in
the nucleus in the 436 and 771
constructs in the cells shown.
Bar: (436-15) 8.87 mm; (771-
15) 11.98 mm; (989-15) 16.18
mm; (1597-15) 16.04 mm;
(1955-15) 15.2 mm; (10366-
15) 21.37 mm.
Figure 5. Immunofluores-
cence of wild-type and null
(HD2/2) ES cells transfected
with 1955-128. The cells were
treated with tamoxifen and
immunostained with mAb
2166. Perinuclear aggregates
were evident in both cell
lines, indicating that the pres-
ence of endogenous hunting-
tin is not required for the for-
mation of aggregates by
transfected 1955-128. Bar:
(Wild-type) 2.82 mm; (HD2/2)
2.87 mm.Hackam et al. Aggregates and Toxicity of Huntingtin Proteins 1103
that an NH2-terminal fragment of huntingtin may be
proapoptotic even in the absence of polyglutamine expan-
sion. However, measurement of cell viability indicated a
polyglutamine repeat-dependent increase in cell death (P ,
0.01 for all constructs). The differences in toxicity are not
due to differences in expression of these constructs in cells
as revealed by Western blot (data not shown). Increased
susceptibility to cell death for any of these huntingtin gene
products were only seen in the presence of apoptotic stress
(data not shown). Therefore, the susceptibility to an apop-
totic stress is influenced by both the length of the hunting-
tin protein and the size of the polyglutamine tract.
Discussion
The factors determining the subcellular localization of
huntingtin, and the relationship between its localization
and cellular viability, are fundamental to understanding
the pathogenesis of HD and may provide new therapeutic
targets for delaying or preventing toxicity in vivo. There-
fore, we performed experiments designed to investigate
factors that may be influencing the nuclear transport of
huntingtin. In particular, we wished to dissect how the
length of the huntingtin protein was correlated with nu-
clear localization of huntingtin and its tendency to form
aggregates. The findings of this study clearly and directly
implicate protein length as a critical factor in influencing
the subcellular localization of huntingtin. Whereas nuclear
localization is crucially dependent on protein length, the
likelihood of formation of aggregates appears to be di-
rectly related to the length of the polyglutamine tract.
The fact that these aggregates form even with a hunting-
tin fragment essentially composed of only 17 amino acids
besides the 128-residue polyglutamine stretch is strong ev-
idence for these aggregates forming by expanded poly-
glutamine tracts joining these molecules together. This
also supports the in vitro data generated by assessing in-
teraction between glutathione-S-transferase fusion pro-
teins with expanded polyglutamine tracts (Scherzinger et al.,
1997).
Endogenous huntingtin is recruited into aggregates
formed by a truncated form of the transfected protein
(Martindale et al., 1998). Here we show, using HD2/2 ES
cells, that aggregates can form in the absence of full-length
endogenous huntingtin, demonstrating that in this system,
endogenous huntingtin is not necessary for formation of
aggregates. Whereas extrapolation from this in vitro
model using cell types not normally affected in HD to the
in vivo situation must be done with caution, this may sug-
gest that mutant huntingtin can form aggregates alone in
vivo providing further evidence for a gain of function re-
sulting from polyglutamine expansion.
Huntingtin derived from three constructs spanning up
to 989 nucleotides (224 amino acids) were all seen partially
or predominantly within the nucleus. These constructs would
be expected to produce predicted proteins of ,40 kD. For
example, the 989 construct containing 128 repeats would
encode a protein of z39 kD. By contrast, mutant proteins
of 60 kD or greater (derived from the 1597, 1955, and
10366 constructs) were observed in the perinuclear region
in the cytosol with no nuclear localization. Furthermore,
the expression of the COOH-terminal construct express-
ing a predicted product of 284 kD also produced a protein
exclusively located diffusely throughout the cytoplasm. No
aggregates were seen with this construct.
Proteins that traverse from the cytoplasm into the nu-
cleus must go through the nuclear envelope and enter
through the nuclear pore. Nuclear pore complexes are
composed of many different polypeptides and have a large
mass of .100 MD. Transport across the nuclear pore may
either be the result of passive diffusion or active transport
(Zasloff, 1983; Newmeyer et al., 1986; Gorlich and Mattaj,
1996). Small proteins, generally ,40 kD, can diffuse pas-
sively through the nuclear pore. For example, cytochrome
c (13 kD) diffuses freely through the nuclear pores,
whereas ovalbumin (43 kD) has a delayed transport, and
BSA (66 kD) is completely prevented from passing
through the nuclear pore (Gorlich and Mattaj, 1996). The
relationship between size of huntingtin and its localization
in the nucleus determined in this study is consistent with
transport across the nuclear membrane being size related
and resulting from passive diffusion across the nuclear
membrane. Thus, a construct expressing a huntingtin
product of z40 kD has some nuclear but predominantly
perinuclear localization (construct 989), and huntingtin of
predicted sizes of 60 kD or greater (derived from 1597,
1955, and 10366 constructs) are essentially excluded from
the nucleus, similar to that seen with BSA (Gorlich and
Mattaj, 1996).
However, size alone is not the only determinant of local-
ization of the expressed product. For example, the gene
product of the 771 construct was seen most frequently in
the nucleus and seen more often than after expression of a
smaller gene product from the 436 construct. This suggests
that active transport may influence the localization of this
protein.
Figure 6. Increasing toxicity with decreasing huntingtin length. In
the presence of tamoxifen, progressive truncation of huntingtin
resulted in increased cellular toxicity (P , 0.01). Interestingly,
this trend was seen for proteins containing both 15 and 128 poly-
glutamines (P , 0.01). 293T cells were transfected with each hun-
tingtin construct, or LacZ control, and cell viability in response to
apoptotic stress was measured using a modified MTT assay and
presented relative to control (untransfected). All wells were
transfected with 0.1 mg DNA except for those transfected with
the 436-15 and 128 constructs, where 0.08 mg of DNA was used
because all the cells died with 0.1 mg DNA. Results for the 436
construct are normalized, taking into account decreased DNA
concentration. Asterisks indicate the level of significance be-
tween huntingtin containing 15 and 128 glutamines: * P , 0.01;
** P , 0.001.The Journal of Cell Biology, Volume 141, 1998 1104
Active import of proteins requires energy and also a nu-
clear localizing signal to which different cytosolic receptor
complexes bind for transport (Zasloff, 1983; Newmeyer
et al., 1986). We have searched the NH2-terminal domain
of huntingtin for a sequence motif suggestive of a nuclear
localization signal (NLS) (Goldfarb et al., 1986; Dingwall
and Laskey, 1991; Chen et al., 1996). Although no strin-
gent consensus sequence for an NLS is defined, a basic
hexapeptide sequence and a bipartite sequence are sug-
gestive of this motif (Efthymiadis et al., 1997). Interest-
ingly, within the first 548 amino acids of huntingtin, a sin-
gle stretch of amino acids (90-PKKELSATKK-99) with
some similarity to the NLS of the familial breast cancer
BRCA-1 protein (PKKNRLRRKS) has been identified
(Chen et al., 1996). Further analysis of the role of this se-
quence as a functional NLS is necessary in an effort to de-
termine its role in nuclear transport.
We have previously shown that the expression of mu-
tant huntingtin results in increased susceptibility to apop-
totic stress in transfected 293T cells (Martindale et al.,
1998). This was initially shown in proteins derived from
the 1955 compared with the full-length construct. In this
study we have extended these findings and now show that
constructs with 128 versus 15 repeats were more toxic to
cells after apoptotic stress at all lengths of the protein. Fur-
thermore, there is an increase in cell death with shorter
constructs, again showing as postulated previously (Mar-
tindale et al., 1998), that length of the protein is directly re-
lated to the susceptibility to cell death. Interestingly, ex-
pression of the truncated form of huntingtin even with a
normal sized polyglutamine tract confers increased sus-
ceptibility to cell death from apoptotic stimuli demonstrat-
ing that this NH2-terminal sequence alone can be toxic to
cells in vitro.
This is not inconsistent with the model for this disease
whereby cleavage of wild-type huntingtin normally plays a
role in influencing cellular viability. Disease could arise
when a threshold is reached and inappropriate apoptosis
occurs at least influenced by the presence of a truncated
product containing an expanded polyglutamine tract. The
margin between the effects at any one time between nor-
mal and mutant huntingtin may be narrow but cumulative
over time resulting eventually in a disease with late onset.
These findings in this manuscript do not explain why
each of these polyglutamine expansion diseases result in a
selective pattern of neuronal loss, despite the fact that
their gene products are expressed in similar regions in the
central nervous system (Ross, 1995). One factor that may
influence selectivity of neuronal loss is proteolytic cleav-
age of polyglutamine-containing proteins. For example,
our own data suggest that atrophin-1, the androgen recep-
tor, and huntingtin are each cleaved by different caspases
with varying efficiencies (Wellington et al., 1998) resulting
in the formation of a truncated fragment containing the
polyglutamine tract. Because the gene products have dif-
ferential susceptibility to individual caspases, the particu-
lar pattern of cell loss for each disease could be due in part
to the altered cellular or subcellular distribution of these
particular enzymes, leading to altered interaction with
their substrates.
These in vitro data, together with data generated by
Martindale et al. (1998) and Cooper et al., (1998), are con-
sistent with a model that proposes that a crucial step in the
pathogenesis of this disorder is the progressive truncation
of huntingtin resulting in altered localization, aggregate
formation, and decreased cellular viability. This model is
consistent with data generated from studies of brains from
patients with HD which demonstrate both perinuclear ac-
cumulation of huntingtin and intranuclear inclusions (Di-
Figlia et al., 1997; Sapp et al., 1997) suggesting that this in
vitro model may significantly recapitulate what occurs in
vivo in animals and humans.
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